Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B
In the phase-III GLOBE/015 studies, telbivudine demonstrated superior efficacy vs lamivudine during 2-year treatment in HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB). After completion, 847 patients had an option to continue telbivudine treatment for further 2 years. A total of 596 (70%...
Saved in:
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Journal |
Published: |
2018
|
Online Access: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84875229260&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/48042 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |